Last updated: February 4, 2026
Overview
BRINEURA (cerliponase alfa) is a gene therapy developed by BioMarin Pharmaceutical for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2), a rare, progressive neurodegenerative disorder. It received FDA approval in 2017 for children aged 3 and older. The drug is administered intracerebrally via brain infusion pumps under a compassionate use framework and later through formalized clinical pathways.
Clinical Trial Status and Developments
Phase and Regulatory Milestones
- FDA Approval: August 2017; designated as an orphan drug. It was approved based on Phase 1/2 trial data showing slowed disease progression.
- Latest Trials: No active pivotal clinical trials are ongoing for BRINEURA. BioMarin has explored additional indications and expanded into broader post-approval studies, but as of Q1 2023, no new trials are publicized.
Safety and Efficacy Data
- Primary Study (2015): Showed stabilization of motor and language decline in children receiving BRINEURA.
- Long-term Follow-Up: Reports confirm sustained benefits with consistent safety; adverse effects include intracranial infections and device-related complications, typical for intracerebral administration.
Post-Approval Changes and Market Access
- Localized approvals in Europe, Japan, and Canada have adopted similar safety monitoring protocols.
- Ongoing post-market surveillance is mandated by regulatory agencies, with periodic safety update reports (PSURs).
Market Analysis
Market Size and Demand
- Target Population: Children aged 3-12 diagnosed with CLN2. Prevalence estimates range from 1 to 3 per 100,000 in the general population.
- Estimated Patient Pool: Approximately 200-300 patients globally, with higher concentrations in North America and Europe.
Market Penetration
- Sales (2022): Approximately $200 million, with a growth rate of around 10% year-over-year owing to increasing diagnosis rates and expanded healthcare access.
- Pricing: Listed at around $750,000 annually per patient.
Competitive Landscape
- Scheduled or Under Development: No other approved therapies for CLN2. Some investigational gene therapies and enzyme replacement agents are in early development stages but lack clinical data.
- Market Barriers: High delivery cost, invasive administration, and limited awareness inhibit broader adoption.
Insurer Coverage and Reimbursement
- Broad insurance coverage in major markets with reimbursement frameworks centered on demonstrated clinical benefit and safety.
- Real-world utilization depends heavily on early diagnosis and availability of specialized treatment centers.
Projection and Future Trends
Growth Forecast (2023-2028)
- Sales Growth: Expected compound annual growth rate (CAGR) of 8-12% driven by increased diagnosis, geographic expansion, and payer acceptance.
- Market Expansion: Potential in pediatric neurodegenerative disorders sharing similar pathophysiology, contingent on successful trial outcomes.
Regulatory Outlook
- Calls for expanded indication approval for broader age ranges and related diseases.
- Potential for label expansion based on ongoing observational studies.
Innovation and Development
- Research into less invasive delivery methods might extend market reach.
- Development of next-generation gene therapies with improved safety profiles.
Key Takeaways
- BRINEURA's clinical efficacy is well established for the approved population; no recent pivotal trials are ongoing.
- Market penetration remains steady with growth projections influenced by increased diagnosis and acceptance.
- Competitive threats are minimal presently but could change with emerging gene therapy candidates.
- The high cost of therapy limits accessibility but is moderated by insurance reimbursement in major markets.
- Future growth depends on expanding indications, improving delivery techniques, and gaining regulatory approvals.
FAQs
-
Are there ongoing clinical trials for BRINEURA?
No active pivotal or regulatory trials are scheduled; ongoing post-market studies focus on long-term safety and potential broader indications.
-
What is the primary challenge for market expansion?
Invasive administration and high treatment costs restrict adoption, emphasizing the need for less burdensome delivery methods.
-
Could BRINEURA's indication expand beyond CLN2?
Potential exists if efficacy is observed in related neurodegenerative disorders, pending further studies.
-
Is the treatment cost a barrier?
Yes, the cost of approximately $750,000 annually limits access, although reimbursement strategies mitigate this in many regions.
-
What future regulatory developments are expected?
Possible label expansions, especially with ongoing observational data supporting broader use in pediatric populations.
References
- BioMarin Pharmaceuticals. BRINEURA Prescribing Information. 2017.
- FDA. Approval Letter for Cerliponase Alfa (BRINEURA). August 2017.
- EvaluatePharma. Biotech Market Data 2022.
- Global Genes. Rare Disease Prevalence Estimates. 2022.
Disclaimer: Data is based on publicly available information as of Q1 2023. Clinical and market conditions are subject to change.
